Research on the Path of High-quality Development of Capital and Enterprise

Against the backdrop of profound global economic restructuring and domestic economic transformation, the structural mismatch between short-term speculative capital and long-term strategic needs—such as corporate innovation, R&D, and green transition—is becoming increasingly evident. Patient capital, characterized by its long-term nature, risk tolerance, and strategic synergy, has emerged as a pivotal link between capital supply and corporate long-term value creation. This paper integrates theories from capital supply and strategic synergy to systematically explore four key mechanisms through which patient capital influences high-quality corporate development: capital supply, risk cushioning, strategic guidance, and resource integration. It delineates three differentiated development pathways—innovation-driven, green transition, and industrial synergy—and proposes an optimized strategy involving collaboration among enterprises, patient capital, and the government. The findings provide theoretical references for promoting sustainable and high-quality corporate development.